Published in Clin Exp Immunol on January 01, 2005
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet (2010) 2.83
Teriflunomide and its mechanism of action in multiple sclerosis. Drugs (2014) 1.08
Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes. Int J Mol Sci (2013) 0.90
Combination therapies in multiple sclerosis. J Neurol (2008) 0.89
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis. PLoS One (2012) 0.86
Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int J Nanomedicine (2012) 0.86
Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2010) 0.85
Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord (2008) 0.84
A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol (2011) 0.83
Managing MS in a changing treatment landscape. J Neurol (2011) 0.79
Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC. J Clin Immunol (2007) 0.78
B cells as a target of immune modulation. Ann Indian Acad Neurol (2009) 0.76
Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia. Clin Med Insights Oncol (2012) 0.76
Immunosuppression in clinical practice: approaches to individualized therapy. J Neurol (2008) 0.75
Neurobehavioral burden of multiple sclerosis with nanotheranostics. Neuropsychiatr Dis Treat (2015) 0.75
[Recent advances in the pathogenesis and immunotherapy of multiple sclerosis]. Nervenarzt (2007) 0.75
A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods (1995) 16.00
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med (2003) 4.86
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (2002) 3.74
New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci (2002) 2.21
Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Carcinogenesis (1990) 2.00
A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta (2001) 1.82
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 1.49
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol (2001) 1.10
T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci (1997) 1.07
Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol (2001) 1.02
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol (1986) 1.00
Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol (1986) 0.94
Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem Biophys Res Commun (1986) 0.92
Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem (2000) 0.92
Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev (1983) 0.91
Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci (1992) 0.91
Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol (1998) 0.89
T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain (2000) 0.88
High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood (1993) 0.87
Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol (2003) 0.86
Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]. Eur Neurol (1999) 0.82
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A (1997) 4.70
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest (1994) 3.58
Botulinum toxin for palmar hyperhidrosis. Lancet (1997) 3.17
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 2.12
A role for BDNF in mechanosensation. Nat Neurosci (1998) 2.08
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol (1993) 1.92
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Myasthenia gravis: passive transfer from man to mouse. Science (1975) 1.90
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol (1998) 1.83
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler (2002) 1.80
Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology (2010) 1.80
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.77
Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler (2001) 1.76
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci U S A (1996) 1.68
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis (1979) 1.67
Prednisone in Duchenne muscular dystrophy. Lancet (1974) 1.65
Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature (1984) 1.63
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet (1995) 1.60
Linkage of proximal myotonic myopathy to chromosome 3q. Neurology (1999) 1.60
Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol (1998) 1.60
Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler (2006) 1.60
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53
Early natural course of transient encephalopathy after coronary artery bypass grafting. Crit Care Med (2000) 1.52
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve (2000) 1.50
[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002]. Nervenarzt (2002) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today (2000) 1.49
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand (2003) 1.49
Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve (2002) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res (1985) 1.42
Treating HIV encephalopathy with antiretroviral therapy: a clinical case demonstrating the success of HAART. Clin Infect Dis (2004) 1.41
Intravenous Immunoglobulins in MS. Int MS J (2005) 1.41
Chronic recurrent multifocal osteomyelitis: a noninfectious inflammatory process. Pediatr Infect Dis J (1987) 1.37
Specific subtypes of cutaneous mechanoreceptors require neurotrophin-3 following peripheral target innervation. Neuron (1996) 1.36
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood (2000) 1.35
Giant axonal neuropathy. A clinically and morphologically distinct neurological disease. Arch Neurol (1974) 1.34
Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol (1986) 1.34
Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet (1995) 1.33
Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst (2001) 1.32
Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res (2001) 1.32
Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol (1989) 1.31
A specific circulating antigen in hamsters infected with Schistosoma mansoni. Detection of antigen in serum and urine, and correlation between antigenic concentration and worm burden. Am J Trop Med Hyg (1969) 1.30
The sequelae of Haemophilus influenzae meningitis in school-age children. N Engl J Med (1990) 1.27
The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J (2000) 1.27
Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci (1997) 1.22
Adenoviral pneumonia and its complications in infancy and childhood. J Can Assoc Radiol (1969) 1.20
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis (1985) 1.19
Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology (2004) 1.19
Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol (2001) 1.18
Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics (1986) 1.17
Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. Eur J Pharmacol (1983) 1.16
Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol (2009) 1.15
Meningeal hyperperfusion visualized by MRI in a patient with visual hallucinations and migraine. Headache (1996) 1.15
Lenticular nucleus lesion in idiopathic dystonia detected by transcranial sonography. Neurology (1996) 1.15
Diffusion of ions in myelinated nerve fibers. Biophys J (1979) 1.14
Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest (1999) 1.14
Production and characterization of monoclonal antibodies to the extracellular domain of P0. J Neurosci Res (1993) 1.13
Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis (1977) 1.13
Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci (1996) 1.12
Administration of measles, mumps, and rubella virus vaccine (live) to egg-allergic children. JAMA (1990) 1.12
Epidemiologic study of 4684 hospital-acquired infections in pediatric patients. Pediatr Infect Dis J (1989) 1.12
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol (2001) 1.10
Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr (1982) 1.09
Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy. Neurosci Lett (1999) 1.09